Kopra Bio Analysis: $500K Raised
What is Kopra Bio?
Kopra Bio specializes in cancer immunotherapy, transforming cancer cells into biofactories that promote their own destruction.
Employees
2
Founded
2024
Business Model
Direct drug sales post-regulatory approval; partnerships for development and commercialization.
Product Features & Capabilities
- genetically engineered viruses, viral immunotherapy, treatment for glioblastoma, improves survival from 0% to over 90%, cancer-selective design, strong safety profile, scalable manufacturing
How much Kopra Bio raised
1 - $500K
September 25, 2024Lead Investor: Y Combinator
Who are the founders of Kopra Bio
AB
Andrew Bartynski
Founder
AH
Alexander Haddad
Founder
Competitors Overview
Kopra Bio operates in the cancer immunotherapy market, focusing on transforming cancer cells into biofactories that facilitate their own destruction. Its main competitors include:
- Replimune: This company specializes in tumor-directed oncolytic immunotherapy. Replimune's treatments work by di
Market Focus
Kopra Bio primarily focuses on the cancer immunotherapy industry, specifically developing technologies that transform cancer cells into biofactories to facilitate their own destruction.
Investors
- QB3
- Andreessen Horowitz
- Boutique Venture Partners
- Lexi Ventures
- MCMA Ventures
- Pioneer Fund
- Y Combinator
See something that needs updating? Suggest edits to this profile.